Clinical trial
Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase
NCT00481052 · Gruppo Italiano Malattie EMatologiche dell'Adulto, Other · Completed
Key facts
| NCT number | NCT00481052 |
|---|---|
| Title | Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase |
| Official title | The Protein Tyrosine Kinase Inhibitor Nilotinib as First-line Treatment of Ph+ Chronic Myeloid Leucemia (CML) in Early Chronic Phase: a Phase II Exploratory, Multicenter Study. GIMEMA Protocol CML 0307. EUDRACT 2007-000597-22. |
| Acronym | CML0307 |
| Lead sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Nilotinib |
| Enrollment | 74 |
| Start date | Jun 23, 2007 |
| Primary completion | Apr 30, 2018 |
| Completion | Apr 30, 2018 |
| First posted | Jun 1, 2007 |
| Last update posted | Jan 18, 2022 |
| Countries | Italy |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: